Actively Recruiting
Randomized Phase 1 Study Evaluating Safety, Immune Response, and Reactogenicity of YKYY025 RSV mRNA Vaccine Injection in Healthy Adults
Led by Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · Updated on 2026-09-10
180
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1 clinical trial to assess the safety, reactogenicity, and immune response of the YKYY025 injection, a respiratory syncytial virus RSV mRNA vaccine, in healthy adult participants. This randomized, double-blind, ascending-dose study involves both men and women aged 18 and older. The trial is sponsored by Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. and aims to understand how the vaccine behaves in the body and its potential for preventing RSV infection. Participants will receive a single intramuscular injection of either the YKYY025 vaccine or a placebo in a randomized, parallel group design. The study includes ascending doses to evaluate the vaccines safety and immune response at different levels. The trial is structured with two parts based on age groups adults aged 18 to 49 years and those 50 years or older. During the study, participants will be monitored for adverse events up to 30 days post-vaccination and serious adverse events for up to 12 months. Heart activity will be assessed through 12-lead electrocardiograms within 4 days after vaccination. Immune responses will be measured by evaluating vaccine response rates and antigen-specific T cell levels at multiple time points up to 6 months after vaccination. Participants are expected to complete all study procedures and follow-up visits over the course of the trial.
CONDITIONS
Brief Title
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
Research Team
Y
Yuting Zhou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here